Celebrities and the media have raised awareness of viruses. The term virus, sometimes used to denote illicit and prying computer software operating in cyberspace, also refers to a sub-microscopic organism that lives in human bodies, and its effect in the real world is far worse than any code running rampant in cyberspace. Viral diseases are the scourge of our times. North America has gotten away lightly so far; seasonal influenza can kill, but it is more often an inconvenience, producing sniffles and aches. The real viral threats, Avian influenza and HIV/AIDS, are currently more prevalent in distant continents, but who knows when they might strike in the homeland?

This company has a platform technology that attacks the very essence of how a virus multiplies in a living system. This proprietary know-how, which prevents viral fusion with living cells, adds immense value to the stock. The company has focused development on the high-profile HIV virus which causes AIDS. However, the technology has extensive and versatile applications in a number of important fields that may lead to the future development of disease prevention.

The stock may either cut a new path in the stock market environment of this millennium, or may be acquired by an established pharmaceutical company. Significantly, some 95% of the company’s traded stock is held by institutions. The stock has changed hands at around $6.5 in late March, 2008, against a 52-week high of $8.59. It has been considered one of the best small capital stock investment opportunities available in the entire Healthcare Sector. Though the company is still in a largely developmental phase, the Net Profit Margin has been over 55% for the last four quarters, while Return on Average Equity has exceeded 52%.

Let us hear your thoughts below: